Tehran University of Medical Sciences

Science Communicator Platform

Stay connected! Follow us on X network (Twitter):
Share By
The N-Methyl-D-Aspartate Receptor Antagonist Ketamin Exerts Analgesic Effects Via Modulation of the Nitric Oxide Pathway Publisher Pubmed



Mahmoudzade S1 ; Goudarzi S2, 3 ; Mohammad Jafari R2 ; Shafaroodi H1, 2, 4 ; Dehpour AR2, 4 ; Sanatkar M5
Authors

Source: Fundamental and Clinical Pharmacology Published:2022


Abstract

Ketamine, an NMDA receptor antagonist, has been approved to have analgesic effects. It is known that nitric oxide pathway is involved in antinociception but with dual effects. In this study, we investigated the role of nitric oxide in ketamine-induced analgesia. Ketamine was administered to mice acute and chronically with/without nitric oxide synthase (NOS) inhibitors. Experimental models of nociception pain, including hot plate, tail flick, and formalin tests, were performed. Western blot was used to measure levels of nitric oxide synthase enzymes in the brain. Ketamine doses of 0.03 and 0.3 mg/kg had significant analgesic effects (p < 0.01). High-dose chronic ketamine could induce analgesia in later phases of the treatment in tail flick test (p < 0.01). Pretreatment with various NOS inhibitors decreased the analgesic effect. In western blot analysis, the expression of NOS proteins was decreased. Low-dose ketamine is effective in analgesia induction. The expression of nNOS and iNOS proteins is dependent on the inhibition of the NMDA/NO pathway. © 2022 Societe Francaise de Pharmacologie et de Therapeutique. Published by John Wiley & Sons Ltd.
Other Related Docs
20. Piroxicam Reduces Acute and Chronic Pain Response in Type 1 Diabetic Rats, Journal of Basic and Clinical Physiology and Pharmacology (2021)